We have located links that may give you full text access.
Hippocampal sulcal cavities: prevalence, risk factors and association with cognitive performance. The SMART-Medea study and PREDICT-MR study.
Brain Imaging and Behavior 2018 July 7
Hippocampal sulcal cavities (HSCs) are frequently observed on MRI, but their etiology and relevance is unclear. HSCs may be anatomical variations, or result from pathology. We assessed the presence of HSCs, and their cross-sectional association with demographics, vascular risk factors and cognitive functioning in two study samples. Within a random sample of 92 patients with vascular disease from the SMART-Medea study (mean age = 62, SD = 9 years) and 83 primary care patients from the PREDICT-MR study (mean age = 62, SD = 12 years) one rater manually scored HSCs at 1.5 T 3D T1-weighted coronal images blind to patient information. We estimated relative risks of age, sex and vascular risk factors with presence of HSCs using Poisson regression with log-link function and robust standard errors adjusted for age and sex. Using ANCOVA adjusted for age, sex, and education we estimated the association of the number of HSCs with memory, executive functioning, speed, and working memory. In the SMART-Medea study HSCs were present in 65% and in 52% in the PREDICT-MR study (χ2 = 2.99, df = 1, p = 0.08). In both samples, no significant associations were observed between presence of HSCs and age (SMART-Medea: RR = 1.00; 95%CI 0.98-1.01; PREDICT-MR: RR = 1.01; 95%CI 0.99-1.03), sex, or vascular risk factors. Also, no associations between HSCs and cognitive functioning were found in either sample. HSCs are frequently observed on 1.5 T MRI. Our findings suggest that, in patients with a history of vascular disease and primary care attendees, HSCs are part of normal anatomic variation of the human hippocampus rather than markers of pathology.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app